Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: Utilization for ovarian cancer treatment

NORIOMI MATSUMURA, MASAKI MANDAI, JUNZO HAMANISHI, KEN YAMAGUCHI, KEN FUKUHARA, HARUHIKO YAGI, TOSHIHIRO HIGUCHI, KENJI TAKAKURA and SHINGO FUJII

Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan

Received June 27, 2007; Accepted September 10, 2007

Abstract. Systemic administration of Fms-like tyrosine kinase 3 ligand (FLT3L) has been considered to be a major route of delivery for tumor immunotherapy because expression of its receptor, FLT3, was detected predominantly in hematopoietic progenitor cells. However, several studies indicate that FLT3L locally overexpressed in tumor or dendritic cells (DCs) also shows an anti-tumor effect. In the current study, we found that FLT3 expression is not present in monocytes but is instead induced in DCs through the differentiation process resulting from stimulation by GM-CSF and IL-4. Addition of FLT3L further augmented FLT3 induction and also increased CD40 expression in DCs, leading to enhanced induction of lymphoblastoid cell line-targeted cytotoxic T-lymphocyte response and CD107a mobilization in CD8+ T cells. Furthermore, FLT3L also induced FLT3 expression in peripheral blood NK cells that showed an enhanced response detected by CD107a mobilization. In a murine ovarian cancer model, locally expressed FLT3L showed anti-tumor effects. Collectively, the current study indicates that FLT3L has an immunostimulatory effect on peripheral blood cells and FLT3L targeted to mature peripheral blood cells may serve as a useful tool for cancer immunotherapy.

Introduction

Ovarian cancer is the most lethal of all gynecological malignancies (1), being responsible for approximately 50% of all deaths from female genital tract cancer. (2) In the past two decades, there has been an approximate 0.1% annual increase in the incidence of ovarian cancer. The majority (75-80%) of ovarian cancer patients present with advanced-stage disease. Although the initial response to chemotherapy is high, the majority of patients with advanced stage ovarian carcinoma develop residual or recurrent disease, and approximately 75-80% of patients die within 5 years. (3) Thus, there is a need to develop new therapeutic approaches including immunotherapy for the management of this disease.

Since the first report of its anti-tumor effect (4), Fms-like tyrosine kinase 3 ligand (FLT3L) has been regarded as a promising molecule to enhance anti-tumor immunity, including ovarian cancer (5-7). To date, the function of FLT3L has mainly been examined in hematopoietic progenitor cells, as FLT3 is expressed almost exclusively in hematopoietic progenitor cells (8-11). FLT3L is known to cause proliferation of hematopoietic stem cells in vitro (12,13) and as a result, systemic administration of soluble FLT3L, which increases circulating numbers of dendritic cells (DCs) and natural killer (NK) cells, enhances anti-tumoral and viral immunity in vivo (3,14-16). However, systemic FLT3L administration may also cause tolerance because of the increased number of immature DCs (17-20).

On the other hand, inoculation of tumor cells (22-25) and DCs (26) expressing membrane bound or soluble FLT3L in mice models enhances anti-tumor immunity, while local administration of FLT3L plasmids (27,28) and soluble FLT3L (29) enhances local Th1 reaction. These facts indicate that FLT3L acts on peripheral blood cells, including DCs and NK cells. However, the activity of locally administered FLT3L is unknown.

Here we show that FLT3 expression is induced by differentiation of peripheral blood monocytes to DCs with GM-CSF and IL-4 in vitro. We also demonstrate that FLT3 expression is induced in NK cells by FLT3L addition in vitro. On the basis of FLT3 expression in these peripheral blood cells, we also show that FLT3L enhances CD40 expression in DCs, which causes enhanced induction of CTL activity, especially with CD40 ligand, and that FLT3L directly enhances NK activity. Importantly, we also show a localized anti-tumor effect of FLT3L in murine ovarian cancer. From these results, we suggest that FLT3L could be used ex vivo to improve the therapeutic effect of DC-based immunotherapy, and also could be used in vivo by local administration of FLT3L to enhance local immunity.
Materials and methods

Cell lines. Lymphoblastoid cell lines (LCL) were generated from PBMCs taken from a healthy donor after obtaining their written consent, as previously described (30). LCL were maintained in RPMI-1640 medium (Nikken Biomedicals, Kyoto, Japan) supplemented with fetal bovine serum (10%, vol/vol; Iwaki, Funabashi, Japan) and penicillin-streptomycin (100 U/ml penicillin, 100 μg/ml streptomycin; Nacalai Tesque, Kyoto, Japan). K562 cells (kind gift from Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University) were also maintained in RPMI-1640 medium supplemented with fetal bovine serum and penicillin-streptomycin as described above. The murine ovarian cancer cell line, HM-1 (Riken Bioresource Center, Tsukuba, Japan), was maintained in α-MEM (Invitrogen, Carlsbad, CA, USA) supplemented as described above.

Flow cytometry and antibodies. Flow cytometry was performed with FACScompur (Beckton Dickinson, Franklin Lakes, NJ USA). Antibodies used were anti-human FLT3L goat polyclonal antibody from Sigma (St. Louis, MO, USA), FITC-conjugated anti-goat rabbit antibody from DakoCytomation (Glostrup, Denmark) and anti-human mouse monoclonal antibodies from BD Pharmingen (Franklin Lakes, NJ, USA) including CD1a-PE, CD86-FITC, CD40-PE, CD83-FITC, HLADR-APC, CD107a-FITC and CD107a-PE; anti-human mouse monoclonal antibodies from BioLegend (San Diego, CA, USA) including FLT3-PE and CD14-FITC; and mouse monoclonal antibodies from Beckman Coulter (Fullerton, CA) including CD56-APC, CD56-FITC, CD4- FITC, CD8-APC, CD8-FITC and CD3-RD1; and mouse IgG1-FITC and IgG1-PE antibodies (both from Beckman Coulter, Fullerton, CA) including FLT3-PE and CD14-FITC; and mouse monoclonal antibodies from BioLegend (San Diego, CA, USA) including CD56-APC, CD56-FITC, CD4- FITC, CD8-APC, CD8-FITC and CD3-RD1; and mouse monoclonal antibodies from Beckman Coulter as isotype controls. In all flow cytometric assays, dead cells were excluded by 7-AAD (BD Pharmingen).

RT-PCR. RT-PCR was performed with a One Step RT-PCR kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Specific primers for FLT3L were forward 5'-CCG CAA AGA CCT GTA CGC CA-3' and reverse 5'-TGG GTC CAA GAT GCA AGG CTT G-3'; and for FLT3, forward 5'-CAG TGG GTG TCG AGC AGT ACT C-3' and reverse 5'-AGC CGG TCA CCT GTA CCA TCT G-3'. PCR amplification was performed using the following conditions: denaturing at 94˚C for 1 min, annealing at 55˚C for 1 min, and extension at 72˚C for 2 min, for 30 cycles.

Transfection of FLT3L cDNA and confirmation of transfection-specific FLT3L expression. Retroviral vector plasmids containing human membrane-bound FLT3L cDNA [pL(FLT3L)SN] were kindly provided by Dr Broxmeyer (31). Empty plasmid vector pLSN (BD Clonetech, Mountain View, CA, USA) was used as a control. These plasmids were transfected into K562 cells and the cells were selected and maintained with G418 (500 μg/ml, Nacalai Tesque). Transfection-specific membrane-bound FLT3L expression was confirmed by RT-PCR and flow cytometry. Transfected K562 cells were irradiated (100 Gy) prior to subsequent experiments.

In vitro generation and maturation of DCs with and without FLT3L stimulation. CD14-positive monocytes were collected from PBMCs with anti-CD14 microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Monocytes were plated in AIM-V medium (Invitrogen) at a concentration of 5x10^6/ml on an untreated 6-well plate (Iwaki) supplemented with GM-CSF (500 IU/ml; Peprotech EC, London, UK) and IL-4 (100 IU/ml; Peprotech). Then, K562 cells prepared as described above or soluble human recombinant FLT3L (100 ng/ml; Peprotech) were added. Incubation was performed at 37˚C, 5% CO2, and 100% humidity for 5 days during which immature DCs were generated. In order to prepare DCs to stimulate lymphocytes, necrotic LCL were made after 4 cycles of freeze-thaw and pulsed to DCs (DCs: necrotic cells = 1:2) at the 5th day of culture, then PolyIC (200 μg/ml; Invitrogen) was added at day 6. At day 8, PBMCs were added to DCs. In some experiments, tumor necrosis factor (TNF) α (200 IU/ml; Peprotech) was added to DCs instead of PolyIC to induce maturation. Purity (always >95%) and maturation of DCs were confirmed by flow cytometry with the antibodies as mentioned above. FLT3 expression in monocytes and mature DCs with and without FLT3L stimulation was examined by RT-PCR and flow cytometry.

Culture of PBMCs with and without FLT3L stimulation for the analysis of FLT3 expression in NK cells. PBMCs were cultured, supplemented with 10 IU/ml of IL-2 with or without soluble FLT3L to maintain T cells and NK cells. Seven days later, FLT3 expression was examined in various fractions of PBMCs (NK cells, T cells, and monocytes), with and without FLT3L stimulation, by RT-PCR and flow cytometry. FLT3 expression was also examined in freshly isolated PBMCs.

Stimulation of PBMCs with DCs. Monocyte-deprived PBMCs were incubated with prepared DCs at a ratio of 5x10^6 PBMCs to 1x10^6 DCs in 2 ml AIM-V medium in a 6-well untreated plate at 37˚C, 5% CO2, and 100% humidity. Human recombinant CD40L (300 ng/ml, Peprotech) was added in some experiments. On the 2nd day of incubation, human recombinant IL-2 (10 IU/ml, Peprotech) was added. Half of the medium was replaced using fresh medium containing 2X concentration of cytokines every 3 days. After 9 days of incubation, PBMCs were collected, washed, and incubated on ice for 30 min prior to use in the assays described below.

Assessment of target specific activation of CD8+ T cells or CD56+ NK cells with flow cytometry. Prepared PBMCs (effector) were added to LCL (target) at an E:T ratio of 2:1; i.e., 1x10^8 PBMCs were added to 5x10^6 LCL in 500 μl of fresh AIM-V medium. Five hours later, cells were collected and the culture medium was assayed for IFN-γ by ELISA. Cell surface expression of CD107a in effector cells was examined with flow cytometry. Briefly, collected cells were incubated on ice for 30 min with antibodies described above and washed twice. For flow cytometric analysis, viable lymphocytes were gated and the number of CD107a-positive cells in CD3+CD8+-positive or CD56+-positive cells was measured.
**IFN-γ ELISA.** Culture medium prepared in experiments described above was assayed for IFN-γ by ELISA (BioRad, Hercules, CA, USA) according to the manufacturer's protocol.

**Flow cytometric cytotoxicity assay.** Flow cytometric cytotoxicity assays were performed with CytoxyLux PLUS (Oncoimmunin, Gaithersburg, MD, USA). Briefly, target cells were stained with T Medium at 37˚C for 1 h and washed. Prepared PBMCs were added to target cells at a variable E:T ratio and incubated in Caspase 3 substrate solution at 37˚C for 1 h. Then the reaction was stopped with washing buffer and cells were further washed. Stained target cells were detected with FACS at FL4, and apoptotic cells were detected at FL1.

**Suppression of tumor formation.** To examine the anti-tumor effect of locally administered FLT3L, irradiated FLT3L-transfected K562 cells (5x10⁶) were mixed with HM-1 murine ovarian cancer cells and inoculated subcutaneously into C3H6F1 mice, which is a hybrid strain of C3H/C57BL6 and syngeneic to HM-1 cells. Empty vector-transfected K562 cells were used as controls. In another experiment, FLT3L-transfected K562 cells and HM-1 cells were inoculated separately into each side of the flank. Tumor size was measured in 3 dimensions twice a week until the long axis of the tumors exceeded 2 cm. The animals received proper care according to the guidelines of the Kyoto University Committee on Animal Care. Animal experiments were performed in compliance with the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines (Workman et al, 1988).

**Statistical analysis.** For analysis of between-group differences, P-values were determined using Mann-Whitney's U-test. A P-value <0.05 was considered significant.
Expression of FLT3 receptor in monocyte-derived DCs. As previously reported (8-11), no detectable FLT3 expression was observed in peripheral blood CD14\(^+\) monocytes by flow cytometry. (Fig. 1a and b) In contrast, when monocytes were differentiated to DCs by addition of GM-CSF and IL-4, FLT3 expression was induced in DCs (Fig. 1a and b). Furthermore, FLT3 expression in DCs was enhanced by addition of sFLT3L (Fig. 1c).

Impact of FLT3L on CD40 expression in DCs. DCs were generated from peripheral blood CD14\(^+\) monocytes by addition of GM-CSF and IL-4 with or without FLT3L. CD40 expression was examined before and after maturation, which was induced by either TNF or PolyI:C. The expression of CD40 in DCs was uniformly enhanced by sFLT3L addition (Fig. 2b). CD86 and HLA-DR expression in DCs was also examined. CD86 expression appeared stronger in sFLT3L-treated DCs, but this was not statistically significant (data not shown). HLA-DR expression was not changed with sFLT3L (data not shown). mFLT3L was transfected into K562 cells (Fig. 3a and b). Next, K562 cells were irradiated and added during the generation of DCs, and the effect of mFLT3L signal was examined. CD40 expression in DCs was enhanced by mFLT3L with or without maturation (Fig. 3c).
Influence of mFLT3L stimulation to monocyte-derived DCs on the ability to induce CTL activity in vitro. In order to examine the effect of FLT3L on the ability of DCs to induce CTL in vitro, we checked LCL specific cytotoxic activity. Briefly, mFLT3L-transfected and irradiated K562 cells were added during the generation of monocyte-derived DCs. DCs were pulsed with necrotic LCL and matured with PolyI:C. Then PBMCs were cocultured with the DCs for 9 days. PBMCs (effector) were then incubated with LCL (target) for 5 h and the IFN-γ concentration in the supernatant was measured by ELISA. Left 2 bars, FLT3L significantly increased IFN-γ secretion from PBMCs. Right 3 bars show controls with FL (DCs were not pulsed, target was not added, and DCs were not added), which were also significantly lower than the FL-treated sample shown at the far left. At least 3 experiments were performed independently and the graph shows mean + SE. FL, mFLT3L-K562; ev, empty vector-K562. *p<0.05.

Influence of FLT3L on peripheral blood CD56+ cells. The influence of FLT3L signal on peripheral blood CD56+ cells was examined. FLT3 receptor mRNA expression in PBMCs was not detectable by RT-PCR (30 cycles) (Fig. 7a). This is in accordance with previous reports (8-10). However, when PBMCs were incubated with sFLT3L-stimulated DCs were used (Fig. 6b, left). Because FLT3L increased CD40 expression in DCs, we tried to add CD40L when PBMCs were incubated with DCs. In this case, as shown in Fig. 6b, mFLT3L stimulation enhanced the ability of DCs to induce cytotoxic activity of PBMCs. Similar results were obtained with sFLT3L (Fig. 6c).
7-day incubation (data not shown). Though K562 cells are established targets of NK cells, CD107a-positive CD56+ cells were scarce without target LCL after the 7-day incubation (Fig. 7c).

Anti-tumor effect of mFLT3L. The potential anti-tumor effect of mFLT3L was examined using a murine ovarian cancer model. HM-1 is an ovarian cancer cell line derived from a B6C3F1 mouse and readily forms tumors when inoculated into B6C3F1 mice (Fig. 8a). Irradiated mFLT3L-K562 cells or empty vector-K562 cells were mixed with HM-1 cells and inoculated subcutaneously in B6C3F1 mice. When inoculated with mFLT3L-K562 cells, tumor growth of HM-1 cells was remarkably suppressed (Fig. 8a). We next determined whether the anti-tumor effect of mFLT3L-K562 cells is truly a local effect. Tumor growth of HM-1 was not suppressed when mFLT3L-K562 cells were administered at a different site (Fig. 8b).

Discussion

FLT3 is a tyrosine kinase receptor structurally related to the macrophage colony-stimulating factor receptor, c-FMS, and to the stem cell factor receptor, c-KIT. Its ligand, FLT3L, is a pluripotent hematopoietic growth factor, which contributes to maintenance, expansion, mobilization and differentiation of hematopoietic progenitor cells (35). Systemically administered FLT3L especially increases the numbers of DCs and NK cells in the blood and the lymphoid and parenchymal organs (36,37) such as spleen and lymph nodes in mice and humans (38,39). Both the membrane-bound and soluble isoforms of FLT3L are biologically active and stimulate the tyrosine kinase activity of FLT3 (22,23). Mice lacking the flt3 ligand by targeted gene disruption are viable but have severe defects including reduced cellularity in the hematopoietic organs, reduced numbers of myeloid and lymphoid progenitors in the bone marrow, and a marked deficiency of NK cells and DCs in lymph nodes, spleen, and thymus (40).

In vitro effects of FLT3L on progenitor cells have also been studied extensively. FLT3L, in synergy with other growth factors, induces marked proliferation of precursors of both myeloid and lymphoid lineages (37). In contrast, the in vitro effects of FLT3L on mature peripheral blood cells have received less attention (41). It is believed that FLT3 expression is confined mainly to progenitor cells, and its expression has not been observed in monocytes in the physiological condition.
Figure 6. mFLT3L stimulation to DCs enhanced the ability of DCs to induce cytotoxic activity of PBMCs when CD40L was added. PBMCs were co-cultured with DCs prepared as explained for Fig. 4. The cytotoxic activity of PBMCs against LCL was examined by flow cytometric cytotoxicity assay. (a) Apoptotic target cells were detected using a substrate of activated caspase 3. (b) Cytotoxic activity of PBMCs was not significantly enhanced by the mFLT3L stimulation to DCs (left). However, when CD40L was added during the co-culture of PBMCs and DCs, mFLT3L significantly enhanced the cytotoxic activity of PBMCs (right). At least 3 experiments were performed independently and the graph shows mean ± SE. *p<0.05, **p<0.01. (c) Like mFLT3L, enhancement of cytotoxic activity induced by DCs generated with sFLT3L was apparent when CD40L was added during the co-culture of PBMCs and DCs. Two independent experiments were performed and similar results were obtained. Representative data are shown.
In accordance with these previous reports, we did not detect expression of FLT3 in purified peripheral monocytes. However, the expression of FLT3 was detected when differentiation of monocytes into DCs was induced by GM-CSF and IL-4. Moreover, FLT3 expression was augmented by addition of FLT3L in the course of DC generation. This is not likely the consequence of proliferation of hematopoietic progenitors, as the total cell number of the culture did not increase throughout the experimental course (data not shown) and the phenotype of cultured cells was uniformly that of DCs (Fig. 1b). Interestingly, addition of FLT3L somehow enhanced induction of IFN-γ secretion and CD107α mobilization (Figs. 4 and 5) during stimulation of effector cells. However, induction of cytotoxicity by CTLs co-cultured with the DCs was not observed unless CD40L was added along with FLT3L. At the same time, we found that CD40 expression in DCs was increased by the addition of FLT3L during the DC generation process (Figs. 2 and 3). In the case of hematopoietic progenitor cells, it is well known that FLT3-mediated responses are highly dependent on other growth factors combined with FLT3L. FLT3L stimulation of early hematopoietic progenitor cells without the addition of other growth factors results in monocyte differentiation without an apparent proliferative response. However, a vigorous proliferative response is produced if FLT3L is combined with growth factors such as IL-3, G-CSF or KIT ligand. Similarly, our results indicate that the immunostimulatory effect of FLT3L on DCs somehow depends on the presence of CD40L, suggesting that CD40-CD40L interaction between DCs and T cells, one of the most potent immunostimulatory signals known between these two cell types (42), plays an important role in FLT3L action here.

It has been repeatedly reported that FLT3L has an anti-tumor effect in vivo in mouse models. Although systemic administration of FLT3L increases the number of DCs and NK cells, the anti-tumor effect of FLT3L is not necessarily explained by systemic stimulation of hematopoietic progenitor...
cells by FLT3L. Rather, a spatially distinct mechanism, including paracrine or autocrine stimulation of local primitive hematopoietic cells, appears to play a major role. In mouse models, inoculation of tumor cells (22-24) and DCs (26) expressing membrane bound FLT3L enhances anti-tumor immunity. In addition, local administration of FLT3L plasmids (27,28) enhances the local Th1 reaction. In our study, FLT3L-expressing K562 cells that were co-inoculated with HM-1 ovarian cancer cells locally also showed a tumor inhibitory effect. Although the precise mechanism of how the FLT3L/FLT3 system works peripherally is yet to be elucidated, our in vitro data indicate that one of the possible mechanisms of the local anti-tumor effect of FLT3L may be the induced up-regulation of CD40 in peripheral DCs. Indeed, the combination of FLT3L and CD40 ligand has been reported to be effective for tumor immunotherapy (43,44).

NK cells are also a well-known target of FLT3L. It has been reported that locally expressed FLT3L enhances NK activity as well as DC function in vivo (25,26). However, it is thought that mature NK cells do not express FLT3 and that FLT3L exerts its influence on NK cell progenitors. In this study, FLT3 expression was not detected in NK cells (Fig. 7a and b), and this is in accordance with previous reports (10). However, FLT3 expression was induced with FLT3L addition (Fig. 7a and b). As far as we know, there is no published data concerning the in vitro effect of FLT3L on NK cell activity, probably due to the presumed lack of expression of FLT3 in NK cells. Functionally, we examined CD107a mobilization in CD56+ lymphocytes against LCL and found that NK activity was enhanced by the direct addition of FLT3L to PBMCs (Fig. 7c). This is the first report that FLT3L induces FLT3 expression in mature NK cells, and the underlying mechanism by which FLT3L acts on NK cells should be further examined.

In agreement with previous reports, our results showed the possibility of in vivo immunotherapy using FLT3L. As mentioned above, FLT3L might influence both peripheral blood NK cells and DCs in local circumstances, although it remains unclear whether administered FLT3L acts on these cells in the same manner as is found in vitro. In this study, we used irradiated K562 cells as a vehicle to deliver an immunostimulatory signal to exclude an allo-stimulatory effect (45). The more widely-pursued methods to stimulate an immune response by delivering a specific genetic signal(s) include transfecting DCs or tumor cells directly. However, ex vivo gene transfection to DCs is technically challenging (46). On the other hand, gene transfection into tumor cells is also difficult because of the need to culture tumor cells from each patient (47). Compared with these time- and labor-consuming methods, utilizing non-immune non-tumor cells as the target of gene transfection and the signal delivery carrier may provide a more efficient and realistic clinical use, if it has comparable efficacy to other methods. This study showed that FLT3L-transfected K562 cells serve as an immunostimulatory signal carrier both in vitro and in vivo. Further studies to compare its efficacy with other methods are necessary. The leukemia cell line, K562, may not be suitable in terms of clinical use. Therefore a proper target cell model should be carefully sought, which includes ex vivo culture of autologous normal cells that can be easily expanded and that are transflectable.

Previous reports suggested the risk that systemically administered FLT3L could induce immunotolerance in vivo by increasing immature DCs (17-21), although others reported contrary findings (4,15). These conflicting data suggest that FLT3L may give rise to immunotolerance if administered systemically, and the enhancement of tumor immunity mainly depends on the circumstances where local immune response is evoked. Therefore, finding a method to elicit a potent immune reaction locally would be a key aspect in FLT3L-based cancer therapy. Effective anti-tumor effects of FLT3L may be obtained when enhanced NK activity causes tumor cell death and secretion of TNFα from dead cells, followed by maturation and enhanced CD40 expression in DCs (48). On the other hand, ex vivo generation of DCs from monocytes with return to patients has been extensively tried for tumor immunotherapy (49,50). Utilization of FLT3L for ex vivo generation of DCs may also be an attractive method in order to avoid tolerance.

In summary, our data indicate that FLT3L has an immunostimulatory effect on peripheral blood cells both in vitro and in vivo, suggesting that targeting of FLT3L to mature peripheral blood cells may be effective in cancer immunotherapy. Combination therapy with CD40 ligand would improve efficiency because FLT3L may induce CD40 expression in DCs as well as FLT3 expression in vitro.

Acknowledgements

We thank Dr Sarah Murphy at Duke University Medical Center for her useful advice in preparation of the manuscript. We also thank Miss Michiko Muraoka for her contribution as a laboratory technician. This study was supported by Grant-in-Aid for Scientific Research to S.F. (15209057), K.T. (17659514) and T.H. (17591729) from Japan Society for the Promotion of Science.

References


